

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

<p>1. Name and Address of Reporting Person*</p> <p><u>Sanna Bastiano</u></p> <hr/> <p>(Last) (First) (Middle)</p> <p><u>C/O VERTEX PHARMACEUTICALS INCORPORATED</u></p> <p><u>50 NORTHERN AVENUE</u></p> <hr/> <p>(Street)</p> <p><u>BOSTON MA 02210</u></p> <hr/> <p>(City) (State) (Zip)</p>	<p>2. Issuer Name and Ticker or Trading Symbol</p> <p><u>VERTEX PHARMACEUTICALS INC / MA [ VRTX ]</u></p> <p>3. Date of Earliest Transaction (Month/Day/Year)</p> <p><u>04/04/2023</u></p> <p>4. If Amendment, Date of Original Filed (Month/Day/Year)</p>	<p>5. Relationship of Reporting Person(s) to Issuer (Check all applicable)</p> <p>Director 10% Owner</p> <p><input checked="" type="checkbox"/> Officer (give title below) Other (specify below)</p> <p><u>EVP, Cell &amp; Genetic Therapies</u></p> <p>6. Individual or Joint/Group Filing (Check Applicable Line)</p> <p><input checked="" type="checkbox"/> Form filed by One Reporting Person</p> <p>Form filed by More than One Reporting Person</p>
<p><b>Rule 10b5-1(c) Transaction Indication</b></p> <p><input checked="" type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.</p>		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	04/04/2023		S <sup>(1)</sup>		211	D	\$314.22 <sup>(2)(3)</sup>	47,591	D	
Common Stock	04/04/2023		S <sup>(1)</sup>		94	D	\$315.66 <sup>(2)(4)</sup>	47,497	D	
Common Stock	04/04/2023		S <sup>(1)</sup>		90	D	\$316.76 <sup>(2)(5)</sup>	47,407	D	
Common Stock	04/04/2023		S <sup>(1)</sup>		96	D	\$317.65 <sup>(2)(6)</sup>	47,311	D	
Common Stock	04/04/2023		S <sup>(1)</sup>		31	D	\$318.68	47,280	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)					

**Explanation of Responses:**

- Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022.
- Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of \$314.22 (range \$313.72 to \$314.70).
- Open market sales reported on this line occurred at a weighted average price of \$315.66 (range \$315.08 to \$315.96).
- Open market sales reported on this line occurred at a weighted average price of \$316.76 (range \$316.41 to \$317.20).
- Open market sales reported on this line occurred at a weighted average price of \$317.65 (range \$317.49 to \$317.74).

**Remarks:**

/s/ Christiana Stevenson,  
Attorney-in-Fact 04/06/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.